Home > Drugs A – Z > Tirofiban (By injection)

Tirofiban (By injection)

Helps prevent blood clots from forming.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Tirofiban injection is used to prevent blood clots from forming in the arteries of the heart after certain types of chest pain and heart attacks. It may also be used in patients who are having certain heart and blood vessel procedures. Tirofiban is an antiplatelet medicine. It reduces the chance that a harmful clot will form by preventing certain cells in the blood from clumping together. This… Read more
Brand names include
Aggrastat
Drug classes About this
Platelet Aggregation Inhibitor

What works? Research summarized

Evidence reviews

Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of tirofiban during percutaneous coronary intervention for acute coronary syndrome

Bibliographic details: Li XM, Li DZ, Yang YN, Ma YT, Zheng H, Yang YZ, Chen QJ, Li WM, Xie X, Zhao Y.  Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of tirofiban during percutaneous coronary intervention for acute coronary syndrome. Experimental and Clinical Cardiology 2014; 20(7): 1084-1104 Available from: http://cardiologyacademicpress.com/?cat=4#

Meta-analysis of randomized controlled trials on the efficacy and safety of intracoronary administration of tirofiban for no-reflow phenomenon

BACKGROUND: Currently, there is still a lack of an optimal treatment for no-reflow phenomenon (NR). The aim of this simple meta-analysis was to evaluate the efficacy and safety of intracoronary (IC) administration of tirofiban compared with other conventional drugs during percutaneous coronary intervention (PCI) for NR.

Safety and efficacy of early administration of tirofiban in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis

The review concluded that early administration of tirofiban was safe in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. There were no differences between early and late tirofiban administration in terms of angiographic and clinical outcomes. The relatively limited evidence means that the recommendations for further research appear appropriate.

See all (45)

Summaries for consumers

Glycoprotein IIb‐IIIa inhibitors for acute ischaemic stroke

Question: We wanted to evaluate the safety and effectiveness of GP IIb‐IIIa inhibitors, alone or in combination with thrombolytic agents, in individuals with acute ischaemic stroke.

PubMed Health Blog...

read all...